biosimilars in china

19
Robert Valdes Large-Scale Manufacturing Story: Keeping Pace with Chinaʼs future Biosimilar Demand

Upload: biotech-resources-group-llc

Post on 03-Jul-2015

1.511 views

Category:

Business


0 download

DESCRIPTION

Biotech Resources Group was invited to Qingdao (1hr North of Shanghai) to present on the challenges of biosimilars in China given the need to keep pace with increased commercial demand.

TRANSCRIPT

Page 1: Biosimilars in China

Robert Valdes

Large-Scale Manufacturing Story:Keeping Pace with Chinaʼs future Biosimilar Demand

Page 2: Biosimilars in China

Introduction

• Biosimilar Drivers & Challenges in China

• Large-Scale Manufacturing Story

• Business Justification - Commercialization (>10 years)

• Key Success Factors

Page 3: Biosimilars in China

IntroductionRobert Valdes (Bob)GMP Consultant and V.P. Business DevelopmentBiotech Resources, USA

22 years experience in biotechnology: ManufacturingHuman Genome Sciences, Lonza, Charm Sciences

Advisory Board—Johns Hopkins (2011)Co-Founder—Biotech Resources (2000)Founder—RRMS Inc. Supporting the MS Community (2002)

BA Microbiology—University of New HampshireMSc Biology / BioProcessing—University of MassachusettsMBA—Johns Hopkins Carey School of Business

Page 4: Biosimilars in China

Biosimilar Drivers & ChallengesDrivers

New Sector / High Economic Potential

• 12th 5-Year Plan: Healthcare Reform

• Expected Discount vs. Innovator• Rising Prosperity / Treatment naïve

• Customer price sensitivity: High• Large Market / High CAGR %

• Success, Time, Cost: Favorable

Patent Expiry: $54Bb before 2020

Page 6: Biosimilars in China

Biosimilar Drivers & ChallengesChallenges

• Marketing & Differentiation • Product Approval does not guarantee revenue

• Innovator has 20 yrs collective experience

• Switching Costs: Physicians need data • May impede adoption / market penetration / delayed revenue

• Innovatorʼs 2nd/3rd generation Biobetter

Page 7: Biosimilars in China

Biosimilar Drivers & ChallengesChallenges

• Competition: Innovator vs BioSimilar

• Kilograms / Annum: High

• Facility Expansion, Build New or Partnership

• Cost ($/gram) control to hedge against expected discount and NDRC/NRDL action

• Project: Strict Adherence to Quality/GMP

• Manufacturing Process is complex

Page 8: Biosimilars in China

Large-Scale Manufacturing Story• Project map: 50,000 ft view

• Business Rationale & Justification• Core Team Hiring and Training

• Quality Systems• Design Development—Procurement—Start-up -Comm/Val

• Equipment / New Technologies• Strategic Alliances & Benchmarking

• BLA Approval & Celebration!

Page 9: Biosimilars in China

Large-Scale Manufacturing StoryProject map: 50,000 ft view

0

25

50

75

100

Business Rationale Design & Project Planning Execute Release for GMP

Project Expenditures

Page 10: Biosimilars in China

Large-Scale Manufacturing StoryBusiness Rationale & Justification

• Facility: Capital appropriation >$100MM ($1000/ft2 US)

• Working Capital = Raws + WIP +BDS+FDP

• Financial Evaluation: pipeline, customer need (kg), pricing, royalty burden, 2-4 years, innovator / FOB / BioBetter

• Scenarios: CMO vs Build vs JV

• Scenarios: Scale vs Titer vs $/gram

• Key Success Factor #1: Alignment on cost, time, resources, and risks. All departments highly participative

Page 11: Biosimilars in China

Large-Scale Manufacturing StoryCore Team Hiring, Ramp-up, and Training

• Key Success Factor #2 : Hire the core team early

• You will always be training / Develop training system with QA (Quality Assurance) as workers commission the facility.

• Hiring takes time. Training takes time. Priority.

0

50

100

Core Team Design / Plan Execute GMP (1/2 Max) Full Speed

Percentage of Fully Staffed Facility

Page 12: Biosimilars in China

Large-Scale Manufacturing StoryQuality Systems

QSIT (21 CFR Part 820)Quality Systems Inspection Technique: Evaluate effective implementation of Quality Systems / Subsystems and satellite programs

• Goal: Determine the firmʼs state of compliance by focusing on the key elements from a top-down perspective.

• Quality Policy, Quality Plan: translated into procedures/activities/Instructions relevant to the product produced

• Management Reviews (suitability and effectiveness of the Quality System)

• Evaluate subsystems for adequacy based on findings, trends; Metrics

• Leverage electronic systems early: CAPA, Training, Documents, Metrology, Inventory

• Leverage electronic systems early: Data Monitoring, EBR, Barcode, Wireless Scan

http://www.fda.gov/downloads/ICECI/Inspections/UCM142981.pdf

Page 13: Biosimilars in China

Large-Scale Manufacturing StoryQuality Systems (conʼt)

QSIT (21 CFR Part 820)Key Success Factor # 3-QA/QC will integrate very early to provide guidance on design as it pertains to:

• Material Systems

• Facility/Equipment System Management

• Production Systems—Batch Records, Tech Transfer

• Microbiology—Environmental Control, Facility/Personnel Hygiene

• Training (always training)

• Personnel Flow, Waste Flow, Segregation, Facility Protection

• Product Sampling / Testing: Analytical Chemistry, Immunoassay, PCR

Page 14: Biosimilars in China

Large-Scale Manufacturing StoryDesign Development

• Conceptual/Prelim Design: Process Description, PFD, Facility Energy/ Utility balances, Major Equipment Lists, General Arrangement , Site Plan, Design Bases (Piping, Electrical, Equipment, Civil, Structural), Cost estimate summary

• Detailed Design: Utility Summary, Equipment Specs, Diagrams, 3D-model

• Procurement & Construction Management, Safety, Quality, and Permitting

• Definitive Cost estimate

• Start-Up/Commissioning / Validation

• Engineering Runs and Release for GMP

Page 15: Biosimilars in China

Large-Scale Manufacturing StoryEquipment and New Technologies

• Manufacturing Strategy must be designed for ease of scale-up and tech transfer

• Insource and Outsource as part of facility utilization model

• Innovator and Biosimilar companies have access to modern technologies

• Expression systems, Upstream, Bioseparation, etc

• Deploying new technology platforms should have thorough regulatory review

• Long lead times and price: bioreactors, columns, Centrifuge, BDS freeze units

• Lead times will force the order of procurement and resource deployment

Page 16: Biosimilars in China

Large-Scale Manufacturing StoryStrategic Alliances & Benchmarking

• Key Success Factor #4: Leverage peerʼs experience to compress learning curve• Facility Design: Design ideas / Lessons learned / PAI trends• Optimize facility utilization and supply continuity• Internships / Training

Page 17: Biosimilars in China

Large-Scale Manufacturing StoryBLA Approval and Celebration

• >10 years

• Design, Build, Operate 24/7 to provide phase III and commercial supply

• Key Success Factor #5: Celebrate along the way

Database Lock BLA Filing PAILAUNCH!

ASSEMBLE APPROVAL

Page 18: Biosimilars in China

Large-Scale Manufacturing StoryKey Success Factors

Key Success Factor #1: Must alignment on cost, time, resources, and risks. All departments project aware

Key Success Factor #2: Hire the CORE team early

Key Success Factor #3: Integrate with QA/QC early in project

Key Success Factor #4: Benchmark / Learn from peers

Key Success Factor #5: Celebrate along the way

Page 19: Biosimilars in China

Thank YouRobert Valdes (Bob)GMP Consultant and V.P. Business DevelopmentBiotech Resources, [email protected]